Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 18/20 | 0.79 |
| ▸ | MMP13 | P45452 | 18/20 | 0.79 |
| ▸ | ADAM17 | P78536 | 18/20 | 0.79 |
| ▸ | MMP9 | P14780 | 17/20 | 0.79 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6614299 | 0.97 | MMP1 (0.80) | MMP1MMP13ADAM17MMP9POLB | |
| Dimethylamine SCHEMBL6642543 | 0.92 | MMP1 (0.79) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL5657799 | 0.90 | MMP1 (0.82) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL27547263 | 0.88 | MMP1 (1.00) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL6609138 | 0.88 | MMP1 (0.67) | MMP1MMP13ADAM17MMP9POLB | |
| SCHEMBL6609170 | 0.87 | MMP1 (0.82) | MMP1MMP13ADAM17MMP9POLB | |
| Dimethylamine SCHEMBL3939312 | 0.87 | MMP13 (0.70) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL6612421 | 0.86 | MMP1 (0.68) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL6608451 | 0.86 | MMP1 (0.81) | MMP1MMP13ADAM17MMP9CA12 | |
| SCHEMBL6608931 | 0.86 | MMP1 (0.66) | MMP1MMP13ADAM17MMP9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051407-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-15 | — | — | EP | claimed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | claimed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | claimed |
| EP-1051407-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |